Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 3/2021

01-03-2021 | Systemic Lupus Erythematosus | Original Article

Clinical features and expression of type I interferon-inducible genes in systemic lupus erythematosus patients harboring rs1143679 polymorphism in China: a single-center, retrospective study

Authors: Wenyu Xu, Yueyue Zhang, Xiaoqin Wang, Peiyu Liu, Dayu Gao, Bingjie Gu, Junyu Zhang, Chunmei Li, Qijie Ren, Leilei Yang, Hai Yuan, Minning Shen, Xingguo Chen

Published in: Clinical Rheumatology | Issue 3/2021

Login to get access

Abstract

Objective

This case-control study aimed to analyze the clinical features and determine the expression of type I interferon-induced genes in systemic lupus erythematosus (SLE) patients harboring the CD11b rs1143679 single-nucleotide polymorphism (SNP) and elucidate whether it is involved in the relapses of SLE.

Methods

One hundred twenty-five relatively inactive SLE patients with SLEDAI scores < 6, including 102 CD11b rs1143679 G allele patients as controls and 23 rs1143679 A allele carriers as cases, were enrolled from the SLE patient specimen bank in the Department of Rheumatology and Immunology. The sample set was retrospectively analyzed for differences in clinical features, and quantitative PCR and Western blot analyses were performed to evaluate the relative expression of type I interferon (IFN)-inducible genes.

Results

The 24-h urinary protein levels in the case group were significantly elevated, and serum C3 levels were significantly reduced compared with those in the control group (P = 0.019 and P = 0.021, respectively). The relative mRNA levels of IFN-inducible genes IFIT1, IFIT4, and ISG15 in the case group were higher than that in the control group (P = 0.0257, 0.0344, and 0.0311, respectively) and matched with the Western blot results.

Conclusions

The relative expression of type I IFN-inducible genes in inactive SLE patients harboring the CD11b rs1143679 polymorphism was higher than that in other lupus patients. These findings suggest that the rs1143679 SNP can precipitate relapses in inactive SLE patients.

Key Points

• The rs1143679 GA genotype was associated with SLE clinical features.
• The rs1143679 GA genotype showed higher interferon-inducible gene expression relative to the GG genotype.
Literature
1.
Tsokos GC (2011) Systemic lupus erythematosus. N Engl J Med 365(22):2110–2121CrossRef
2.
Jonsen A, Bengtsson AA, Nived O, Truedsson L, Sturfelt G (2007) Gene-environment interactions in the aetiology of systemic lupus erythematosus. Autoimmunity 40(8):613–617CrossRef
3.
Martinez-Bueno M, Alarcon-Riquelme ME (2019) Exploring impact of rare variation in systemic lupus erythematosus by a genome wide imputation approach. Front Immunol 10:258CrossRef
4.
Fagerholm SC, MacPherson M, James MJ, Sevier-Guy C, Lau CS (2013) The CD11b-integrin (ITGAM) and systemic lupus erythematosus. Lupus 22(7):657–663CrossRef
5.
Rhodes B, Furnrohr BG, Roberts AL, Tzircotis G, Schett G, Spector TD et al (2012) The rs1143679 (R77H) lupus associated variant of ITGAM (CD11b) impairs complement receptor 3 mediated functions in human monocytes. Ann Rheum Dis 71(12):2028–2034CrossRef
6.
Amarilyo G, Verbovetski I, Atallah M, Grau A, Wiser G, Gil O et al (2010) iC3b-opsonized apoptotic cells mediate a distinct anti-inflammatory response and transcriptional NF-kappaBdependent blockade. Eur J Immunol 40(3):699–709CrossRef
7.
Faridi MH, Khan SQ, Zhao W, Lee HW, Altintas MM, Zhang K et al (2017) CD11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosus. J Clin Invest 127(4):1271–1283CrossRef
8.
Litvak V, Ratushny AV, Lampano AE, Schmitz F, Huang AC, Raman A et al (2012) A FOXO3-IRF7 gene regulatory circuit limits inflammatory sequelae of antiviral responses. Nature 490(7420):421–425CrossRef
9.
Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ et al (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 100(5):2610–2615CrossRef
10.
Crow MK, Kirou KA, Wohlgemuth J (2003) Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 36(8):481–490CrossRef
11.
Han GM, Chen SL, Shen N, Ye S, Bao CD, Gu YY (2003) Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 4(3):177–186CrossRef
12.
Patel JC, Hall A, Caron E (2002) Vav regulates activation of Rac but not Cdc42 during FcgammaRmediated phagocytosis. Mol Biol Cell 13(4):1215–1226CrossRef
13.
Hovanessian AG, Brown RE, Kerr IM (1977) Synthesis of low molecular weight inhibitor of protein synthesis with enzyme from interferon-treated cells. Nature 268(5620):537–540CrossRef
14.
Okumura A, Lu G, Pitha-Rowe I, Pitha PM (2006) Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Proc Natl Acad Sci U S A 103(5):1440–1445CrossRef
15.
Lenschow DJ, Giannakopoulos NV, Gunn LJ, Johnston C, O’Guin AK, Schmidt RE et al (2005) Identification of interferon-stimulated gene 15 as an antiviral molecule during Sindbis virus infection in vivo. J Virol 79(22):13974–13983CrossRef
16.
Ye S, Pang H, Gu YY, Hua J, Chen XG, Bao CD et al (2003) Protein interaction for an interferoninducible systemic lupus associated gene, IFIT1. Rheumatology (Oxford, England) 42(10):1155–1163CrossRef
17.
Sakata K, Nakayamada S, Miyazaki Y, Kubo S, Ishii A, Nakano K et al (2018) Up-regulation of TLR7-mediated IFN-alpha production by plasmacytoid dendritic cells in patients with systemic lupus erythematosus. Front Immunol 9:1957CrossRef
18.
Chaichian Y, Wallace DJ, Weisman MH (2019) A promising approach to targeting type 1 IFN in systemic lupus erythematosus. J Clin Invest 129(3):958–961CrossRef
19.
Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J et al (2003) Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 197(6):711–723CrossRef
20.
Gota C, Calabrese L (2003) Induction of clinical autoimmune disease by therapeutic interferonalpha. Autoimmunity 36(8):511–518CrossRef
21.
Kim-Howard X, Maiti AK, Anaya JM, Bruner GR, Brown E, Merrill JT et al (2010) ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash and immunological manifestations in patients with systemic lupus erythematosus with European ancestry. Ann Rheum Dis 69(7):1329–1332CrossRef
22.
Molineros JE, Kim-Howard X, Deshmukh H, Jacob CO, Harley JB, Nath SK (2009) Admixture in Hispanic Americans: its impact on ITGAM association and implications for admixture mapping in SLE. Genes Immun 10(5):539–545CrossRef
23.
Sanchez E, Webb RD, Rasmussen A, Kelly JA, Riba L, Kaufman KM et al (2010) Genetically determined Amerindian ancestry correlates with increased frequency of risk alleles for systemic lupus erythematosus. Arthritis Rheum 62(12):3722–3729CrossRef
24.
Toller-Kawahisa JE, Vigato-Ferreira IC, Pancoto JA, Mendes-Junior CT, Martinez EZ, Palomino GM et al (2014) The variant of CD11b, rs1143679 within ITGAM, is associated with systemic lupus erythematosus and clinical manifestations in Brazilian patients. Hum Immunol 75(2):119–123CrossRef
25.
Zhou Y, Wu J, Kucik DF, White NB, Redden DT, Szalai AJ et al (2013) Multiple lupus-associated ITGAM variants alter Mac-1 functions on neutrophils. Arthritis Rheum 65(11):2907–2916CrossRef
26.
Li C, Tong F, Ma Y, Qian K, Zhang J, Chen X (2018) Association of the CD11b rs1143679 polymorphism with systemic lupus erythematosus in the Han Chinese population. J Int Med Res 46(3):1008–1014CrossRef
27.
Shirai T, Hirose S (2000) Preface and overview: genetics of SLE; a sine qua non for identification. Int Rev Immunol 19(4-5):289–295CrossRef
28.
Zhou Y, Wu J, Kucik DF, White NB, Redden DT, Szalai AJ et al (2013) Multiple lupus-associated ITGAM variants alter Mac-1 functions on neutrophils. Arthritis Rheum 65(11):2907–2901CrossRef
29.
Fan Y, Li LH, Pan HF, Tao JH, Sun ZQ, Ye DQ (2011) Association of ITGAM polymorphism with systemic lupus erythematosus: a meta-analysis. J Eur Acad Dermatol Venereol 25(3):271–275CrossRef
30.
Roberts AL, Thomas ER, Bhosle S, Game L, Obraztsova O, Aitman TJ et al (2014) Resequencing the susceptibility gene, ITGAM, identifies two functionally deleterious rare variants in systemic lupus erythematosus cases. Arthritis Res Ther 16(3):R114CrossRef
31.
Anaya JM, Kim-Howard X, Prahalad S, Chernavsky A, Canas C, Rojas-Villarraga A et al (2012) Evaluation of genetic association between an ITGAM non-synonymous SNP (rs1143679) and multiple autoimmune diseases. Autoimmun Rev 11(4):276–280CrossRef
32.
Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I (2011) Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 17(9):2619–2627CrossRef
33.
Kevil CG, Hicks MJ, He X, Zhang J, Ballantyne CM, Raman C et al (2004) Loss of LFA-1, but not Mac-1, protects MRL/MpJ-Fas(lpr) mice from autoimmune disease. Am J Pathol 165(2):609–616CrossRef
34.
Rosetti F, Tsuboi N, Chen K, Nishi H, Ernandez T, Sethi S et al (2012) Human lupus serum induces neutrophil-mediated organ damage in mice that is enabled by Mac-1 deficiency. J Immunol (Baltimore, Md : 1950) 189(7):3714–3723CrossRef
35.
Ehirchiou D, Xiong Y, Xu G, Chen W, Shi Y, Zhang L (2007) CD11b facilitates the development of peripheral tolerance by suppressing Th17 differentiation. J Exp Med 204(7):1519–1524CrossRef
36.
Luo S, Wang Y, Zhao M, Lu Q (2016) The important roles of type I interferon and interferoninducible genes in systemic lupus erythematosus. Int Immunopharmacol 40:542–549CrossRef
37.
Pascual V, Farkas L, Banchereau J (2006) Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 18(6):676–682CrossRef
38.
Sweeney SE, Kimbler TB, Firestein GS (2010) Synoviocyte innate immune responses: II. Pivotal role of IFN regulatory factor 3. J Immunol (Baltimore, Md : 1950) 184(12):7162–7168CrossRef
39.
Han C, Jin J, Xu S, Liu H, Li N, Cao X (2010) Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b. Nat Immunol 11(8):734–742CrossRef
Metadata
Title
Clinical features and expression of type I interferon-inducible genes in systemic lupus erythematosus patients harboring rs1143679 polymorphism in China: a single-center, retrospective study
Authors
Wenyu Xu
Yueyue Zhang
Xiaoqin Wang
Peiyu Liu
Dayu Gao
Bingjie Gu
Junyu Zhang
Chunmei Li
Qijie Ren
Leilei Yang
Hai Yuan
Minning Shen
Xingguo Chen
Publication date
01-03-2021
Publisher
Springer International Publishing
Published in
Clinical Rheumatology / Issue 3/2021
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-020-05330-x

Other articles of this Issue 3/2021

Clinical Rheumatology 3/2021 Go to the issue

Original Article

Intestinal hypomotility in systemic sclerosis: a histological study into the sequence of events

Original Article

Brainstem auditory evoked potentials in patients with primary Sjögren’s syndrome without central nervous system involvement

Letters of Biomedical and Clinical Research

Characteristics and evolution of 38 patients with rheumatic diseases and COVID-19 under DMARD therapy

Original Article

Assessing rheumatologists’ attitudes and utilization of classification criteria for ankylosing spondylitis and axial spondyloarthritis: a global effort

Letter to the Editor

Comment on: Ankylosing spondylitis coexists with rheumatoid arthritis and Sjögren’s syndrome: a case report with literature review

Original Article

The effectiveness of conservative interventions for the management of syndromic hypermobility: a systematic literature review
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits